Eli Lilly's Price Reduction and Patient Struggles with Zepbound

This chapter examines Eli Lilly's plan to offer lower-priced versions of Zepbound, aimed at making the weight loss drug more accessible for uninsured patients. Through patient interviews and discussions of alternative treatments, the chapter critiques Eli Lilly's pricing strategies and explores the impact of compounding pharmacies on the market.